Streetbeat News

Revenues

SLS

SELLAS Life Sciences announced successful Phase 1 results for SLS009 in treating acute myeloid leukemia (AML) at the 2024 European School of Haematology Conference. The study met all objectives, including pharmacokinetic, pharmacodynamic, safety, and clinical activity. A notable achievement was a complete remission (CR) in a patient after three months, lasting eight months, with one-year survival at the latest assessment. This marks the first instance of CR with CDK9 inhibition monotherapy in a relapsed/refractory AML patient. Phase 2a data is expected in March and Q2 2024.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:31 pm

NFE

New Fortress Energy, Inc. (NFE) has announced the operational status of its Terminal Gas Sul (TGS) LNG terminal in Santa Catarina, Brazil. The terminal, featuring the Energos Winter Floating Storage Regasification Unit (FSRU), has a capacity of approximately 6 MTPA and a maximum send out of 500 mmscf/day. It is connected to the Brazilian gas market, including over 3.5 GW of power infrastructure without firm gas supply contracts and over 300 TBtu of industrial and residential consumers. The TGS terminal is expected to play a crucial role in meeting the increasing power and gas demands in Brazil, especially as the main gas supply from Bolivia declines.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 1:02 pm

DAVA

Endava (NYSE:DAVA) has been analyzed by 7 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $72.14, slightly up from $72.00. Analyst actions include both raises and lowers in ratings and price targets, reflecting changing market dynamics and company performance. Endava faces challenges with a -3.95% revenue decline, below-average net margin, ROE, and ROA, but maintains a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:01 pm

WNS

Recent analyst ratings for WNS (Hldgs) (NYSE:WNS) show a mix of bullish and bearish perspectives, with an average 12-month price target of $78.83, marking a 2.91% increase from the previous target. The company has shown positive financial performance, including a revenue growth rate of 6.28% and a net margin of 12.15%, outperforming industry averages.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:01 pm

FDMT

Analyst perspectives on 4D Molecular Therapeutics (NASDAQ:FDMT) show a mix of bullish and bearish views with 5 recent ratings. The average 12-month price target is $49.4, reflecting a 31.73% increase from the previous $37.50. Analysts from HC Wainwright & Co., Goldman Sachs, BMO Capital, and RBC Capital have provided updates, with price targets ranging from $25.00 to $81.00. 4D Molecular Therapeutics, a clinical-stage gene therapy company, has shown significant revenue growth and solid financial performance, with a notable market capitalization and positive indicators such as net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:01 pm

CL

Analyst ratings for Colgate-Palmolive (NYSE:CL) have shown a positive trend over the past three months, with recent updates indicating a bullish outlook. The average 12-month price target has risen to $90.25, reflecting a 7.19% increase from the previous target. Analysts from firms like Goldman Sachs, Morgan Stanley, and UBS have raised their price targets, citing the company's strong market presence, revenue growth, and financial performance. Despite challenges in debt management, Colgate-Palmolive's revenue growth and profitability metrics stand out in the Consumer Staples sector.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:00 pm

MEG

Montrose Environmental Gr (NYSE:MEG) received mixed analyst ratings with a shift towards a more positive outlook. The recent analysis shows 3 bullish and 1 somewhat bullish ratings, with an average 12-month price target of $43.25, up from $41. Analysts from JP Morgan, Stifel, and Needham have adjusted their price targets and ratings, reflecting a positive sentiment towards MEG's market standing and financial performance. Despite a net margin of -6.92% and ROE of -3.7%, MEG's revenue growth of 28.87% and lower debt-to-equity ratio are seen positively.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:00 pm

H

Hyatt Hotels (NYSE:H) received mixed analyst ratings over the past three months, with 9 analysts offering perspectives ranging from somewhat bullish to indifferent. The average 12-month price target for Hyatt is now $129.44, up from $113.71, indicating a positive outlook. Analysts from firms like JP Morgan, Wells Fargo, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. Hyatt's financial indicators show a below-average market capitalization, revenue growth of 4.53%, and challenges in profitability and asset utilization.

Portfolio Pulse from Benzinga Insights

March 01, 2024 | 1:00 pm

D

Dominion Energy announced the conclusion of its business review and will host an investor meeting today to discuss its multi-year financial and capital investment guidance. This indicates a strategic move to provide transparency and potentially set the stage for future growth.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 12:44 pm

FUBO

FuboTV reported a 12% year-over-year increase in Q4 paid subscribers, reaching 1.618 million, and a 15% increase in average revenue per user (ARPU) to $86.65.

Portfolio Pulse from Benzinga Newsdesk

March 01, 2024 | 12:32 pm